These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 29305587)

  • 21. Investigation of colorectal cancer in accordance with consensus molecular subtype classification.
    Sawayama H; Miyamoto Y; Ogawa K; Yoshida N; Baba H
    Ann Gastroenterol Surg; 2020 Sep; 4(5):528-539. PubMed ID: 33005848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
    Källberg J; Harrison A; March V; Bērziņa S; Nemazanyy I; Kepp O; Kroemer G; Mouillet-Richard S; Laurent-Puig P; Taly V; Xiao W
    Cell Death Dis; 2023 May; 14(5):306. PubMed ID: 37142595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155.
    Zhan T; Faehling V; Rauscher B; Betge J; Ebert MP; Boutros M
    Int J Cancer; 2021 Apr; 148(8):1948-1963. PubMed ID: 33186476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
    Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
    Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
    Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
    Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
    Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda.
    Nzitakera A; Uwamariya D; Kato H; Surwumwe JB; Mbonigaba A; Ndoricyimpaye EL; Uwamungu S; Manirakiza F; Ndayisaba MC; Ntakirutimana G; Seminega B; Dusabejambo V; Rutaganda E; Kamali P; Ngabonziza F; Ishikawa R; Watanabe H; Rugwizangoga B; Baba S; Yamada H; Yoshimura K; Sakai Y; Sugimura H; Shinmura K
    BMC Cancer; 2024 Oct; 24(1):1266. PubMed ID: 39394554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
    Rebersek M
    Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.
    Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH
    Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
    Cherradi S; Ayrolles-Torro A; Vezzo-Vié N; Gueguinou N; Denis V; Combes E; Boissière F; Busson M; Canterel-Thouennon L; Mollevi C; Pugnière M; Bibeau F; Ychou M; Martineau P; Gongora C; Del Rio M
    J Exp Clin Cancer Res; 2017 Jun; 36(1):89. PubMed ID: 28659146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
    Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
    Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of TSPAN8 in consensus molecular subtype 3 colorectal cancer.
    Suwatthanarak T; Tanjak P; Chaiboonchoe A; Acharayothin O; Thanormjit K; Chanthercrob J; Suwatthanarak T; Niyomchan A; Tanaka M; Okochi M; Pongpaibul A; Chalermwai WV; Trakarnsanga A; Methasate A; Pithukpakorn M; Chinswangwatanakul V
    Exp Mol Pathol; 2024 Jun; 137():104911. PubMed ID: 38861838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
    Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X
    Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
    Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
    Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multilevel prioritization of gene regulators associated with consensus molecular subtypes of colorectal cancer.
    Song K; Cai H; Zheng H; Yang J; Jin L; Xiao H; Zhang J; Zhao Z; Li X; Zhao W; Li X
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33855351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.
    Buikhuisen JY; Gomez Barila PM; Cameron K; Suijkerbuijk SJE; Lieftink C; di Franco S; Krotenberg Garcia A; Uceda Castro R; Lenos KJ; Nijman LE; Torang A; Longobardi C; de Jong JH; Dekker D; Stassi G; Vermeulen L; Beijersbergen RL; van Rheenen J; Huveneers S; Medema JP
    J Exp Clin Cancer Res; 2023 Mar; 42(1):56. PubMed ID: 36869386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
    Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
    Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Feliu J; Gámez-Pozo A; Martínez-Pérez D; Pérez-Wert P; Matamala-Luengo D; Viñal D; Kunz L; López-Vacas R; Dittmann A; Rodríguez-Salas N; Custodio A; Fresno Vara JÁ; Trilla-Fuertes L
    Br J Cancer; 2024 Jun; 130(10):1670-1678. PubMed ID: 38486123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer.
    Purcell RV; Visnovska M; Biggs PJ; Schmeier S; Frizelle FA
    Sci Rep; 2017 Sep; 7(1):11590. PubMed ID: 28912574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.